The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Emerging therapies in frontline and R/R FL: CELMoDs, BCL6 degraders, and bispecific antibodies
Juan Alderuccio, MD, Sylvester Comprehensive Cancer Center, Miami, FL, discusses emerging treatment strategies for follicular lymphoma (FL) in both the relapsed/refractory (R/R) and frontline settings. Dr Alderuccio highlights encouraging activity in R/R FL with the CELMoD golcadomide, BCL6 degraders, and the CD3xCD19 T-cell engager surovatamig, as well as frontline studies evaluating bispecific antibody combinations. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Patients with relapsed/refractory follicular lymphoma after CAR-T and bispecifics, they usually present poor outcomes without good options as a standard of care, except the patients that relapse with localized disease where radiation therapy can have a role. And then those patients that respond to achieve a CR can be consolidated with allogeneic stem cell transplant. However, different novel agents have been shown encouraging activity...
Patients with relapsed/refractory follicular lymphoma after CAR-T and bispecifics, they usually present poor outcomes without good options as a standard of care, except the patients that relapse with localized disease where radiation therapy can have a role. And then those patients that respond to achieve a CR can be consolidated with allogeneic stem cell transplant. However, different novel agents have been shown encouraging activity. Golcadomide, which is a new generation CELMoD, also BCL6 degrader, and surovatamig, which is a T-cell engaged CD3/CD19, which also has been shown significant activity in this setting. In the frontline setting, I think bispecific studies in combination with pola-R-CHP or R-CHOP has high chances to be positive studies. They are currently ongoing randomized Phase III studies, although I’m not sure if they’re going to be for all the patients because of the B-cell depletion, hypogammaglobulinemia that these agents produce and the higher risk of infections. So I think we need to wait for the randomized data to see what are the patients that can benefit the most for this type of approaches.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
